Podcasts about Clinical pharmacology

Recorded on 30 October 2025 for ICMDA Webinars.Dr Peter Saunders chairs a webinar with Dr Catriona WaittDiversity is God-given, and means that each of us can bring something unique to our workplaces and societies. Unhelpful stereotypes of leadership still exist in Medicine and Academia, which may result in some very gifted people feeling that they do not belong in a leadership role.In this webinar, I plan to challenge some stereotypes and encourage you to see that God needs a diverse range of Christians in leadership roles. I aim to give the type of talk I would have valued 20 years ago, and empower you to envision how you can embrace opportunities to serve God in your career.Catriona Waitt is a physician and NIHR Professor of Clinical Pharmacology and Global Health at the University of Liverpool. She lived in Malawi for four years during her PhD, and since 2015 has been based largely in Uganda at the Infectious Diseases Institute, Makerere University, Uganda where she leads the Maternal and Infant Lactation pharmacoKinetics (MILK) and Attaining Equity of Access to Research programmes. Her husband Peter is also a clinical academic, and they have had five children and share the adventure of home educating them as they move around the world.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠To listen live to future ICMDA webinars visit⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://icmda.net/resources/webinars/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

The host has been a community pharmacy advocate for 22 years. Always looking for ways to help community pharmacies be more profitable. The guest is an experienced Pharmacist with a demonstrated history of working in the pharmaceutical industry. Skilled in Diabetes, Pharmacy Practice, Community Pharmacy, and Clinical Pharmacology.

In this powerful episode of The David Watson Podcast, world-renowned cardiologist and author Dr. Peter R. Kowey exposes the truth behind the growing crisis in American healthcare. Drawing from his new book, Failure to Treat: How a Broken Healthcare System Puts Patients and Practitioners at Risk, Dr. Kowey reveals how decades of political lobbying, pharmaceutical greed, and insurance control have created a system that harms both patients and doctors. We break down the key reasons why U.S. healthcare is failing — and what must change to fix it. In this episode: How lobbyists and politicians shaped today's broken system The hidden influence of pharmaceutical companies on doctors and prescriptions. How health insurance companies limit care and increase costs. Why lawsuits and corporate pressure drive doctors out of medicine. The systemic failures built into the U.S. healthcare model since its creation Real stories from Dr. Kowey's experience treating patients inside a flawed system. Practical insights on how to protect yourself and advocate for better care. About Dr. Peter Kowey: Dr. Kowey is an internationally recognized cardiologist, medical researcher, and author. He currently serves as Professor of Medicine and Clinical Pharmacology at Thomas Jefferson University and holds the William Wikoff Smith Chair in Cardiovascular Research at the Lankenau Institute for Medical Research. His decades of experience have made him one of the most respected voices in modern medicine. About the book: Failure to Treat is a revealing exploration of how money, politics, and bureaucracy have corrupted American medicine — and what can be done to restore trust and integrity in healthcare. Listen to this episode if you're interested in: Healthcare reform and policy Big Pharma and political lobbying The U.S. medical system's hidden costs Doctor burnout and malpractice issues Patient advocacy and healthcare ethics Guest: Dr. Peter R. Kowey Home | Peter Kowey Author Host: David Watson Podcast: The David Watson Podcast

In this episode, we talk with two authors who have papers featured in the special issue of the Journal of Genetic Counseling on Research Methods in Genetic Counseling. In the first segment we explore implementation science and its utilization in bridging the gap between research and clinical practice. In our second segment, we talk to an author about retrospective chart reviews and the benefits and drawbacks of this methodology.   Segment 1: A guide to utilizing implementation science for genetic counseling   Alanna Kulchak Rahm is a certified genetic counselor and implementation scientist with a PhD in Health and Behavioral Science. She has spent her career specializing in the implementation of genomics and precision health in healthcare systems. For over 25 years, she has conducted research on the utilization of genetic information by individuals and healthcare systems, new paradigms for identifying individuals with genomic risk, and new service delivery models for genomic testing. She has been a driver for the integration of implementation science and patient engagement to understand and study the integration of genomics into the learning health system, and is a tireless advocate of implementation science in genetic counseling. She has participated in and led many workshops and trainings on implementation science in genetics, serving as a faculty mentor for the NIH Training in Dissemination and Implementation Research in Cancer (TIDIRC) and recently as a co-lead of the Training in Dissemination and Implementation Research in Genomics and Precision Public Health (TIDIR-GPPH). She is currently a Program Director in the Division of Genomic Medicine at the National Human Genome Institute (NHGRI) where she directs the Network of Genomics-Enabled Learning Health Systems and other programs and continues to advance the integration of implementation science and genomics.   In this segment we discuss: Implementation science (IS) as a bridge between research and clinical practice in genetic counseling Misconceptions about IS, key frameworks like RE-AIM, and practical applications in daily work Using IS to identify and reduce inequities in genomic medicine Future integration of IS into training, research, and professional practice Link to the 2025 annual conference on dissemination and implementation    Segment 2: Leveraging hindsight: A retrospective chart review how-to for genetic counselors   Dr. Ramsey is the Section Chief of Individualized Therapeutics in the Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation at Children's Mercy. She is leading the implementation of a pharmacogenomics program that is fully integrated with the electronic health record, developing model-informed decision support for several medications, and Co-director of their Pediatric Clinical Pharmacology Fellowship Program. Before joining Children's Mercy, Dr. Ramsey was an Associate Professor and co-director of the Genetic Pharmacology Service at Cincinnati Children's Hospital. She completed her postdoctoral fellowship in Pharmacogenetics at St. Jude Children's Research Hospital and received her PhD in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota – Twin Cities. Dr. Ramsey is interested in all aspects of pharmacogenetics, from basic research to implementation in patient care.   In this segment we discuss: The role of retrospective chart reviews in genetic counseling research Common pitfalls such as unclear aims, time demands, and data extraction challenges Strategies for success, including SOPs, REDCap, and multidisciplinary collaboration Lessons learned on refining criteria, ensuring data quality, and team engagement   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield. 

The prescription of pain medication among Irish patients, including highly addictive opioids, is rapidly rising, according to new research.The use of opioids has increased by 25 per cent in Ireland, while the prescription of paracetamol rose 50 per cent between 2014-2022, according to a study published last week in the British Journal of Clinical Pharmacology.The prescription of even stronger medication, like codeine and opioids including tapentadol and oxycodone, is rising even higher.This sharp increase in pain medication prescriptions by doctors in Ireland contrasts starkly with the approach in England, where the NHS is cracking down on the overuse of these potentially-addictive medicines.Why are so many doctors prescribing this heavy-dose medication?And is this growing reliance on opioids at risk of become an addiction crisis for patients seeking pain relief?Today, on In The News, is Ireland heading towards an opioid addiction crisis?Royal College of Surgeons Ireland (RCSI) associate professor Frank Moriarty, who co-authored the study into how pain is treated in Ireland, discusses the significant rise in opioid prescriptions.Presented by Sorcha Pollak. Produced by Andrew McNair. Hosted on Acast. See acast.com/privacy for more information.

Host: Matt Birnholz, MD Guest: Jim Foote, MBA Functional precision medicine is reshaping oncology by integrating real-time drug testing, genomic data, and artificial intelligence to guide individualized treatment. Dr. Matt Birnholz sits down with Jim Foote, CEO of First Ascent Biomedical, to explore how this approach delivers clinically actionable insights for relapsed and resistant cancer and empowers oncologists with faster, more targeted decision making.

In this episode I discuss R Shiny and how it can be used for building clinical pharmacology tools. I provide an overview of the technology, suggest a few example use cases, and then walk through a specific practical example of predicting AUC and Cmax for future doses from observed data. I end with a discussion of the benefits and challenges of using R Shiny for clinical pharmacology tools. Links discussed in the show:Basics about R ShinyShinyapps.io for hosting shiny apps Example R Shiny app by Samer Mouskassi: ggplot with your dataExample R Shiny app for AUC-Cmax predictions You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

In this episode, Dr Marilena Giannoudi hears about a case that changed the practice of Professor James Dear. They discuss the challenges of caring for a patient without a diagnosis, who to talk to if you are feeling uncertain in how to treat a patient, and how you can own up to and move on from mistakes you may make. Professor James Dear is a Consultant in Clinical Pharmacology at the Royal Infirmary of Edinburgh and Personal Chair of Clinical Pharmacology at the Centre for Cardiovascular Science at the University of Edinburgh. Dr Marilena Giannoudi is a cardiology registrar based in Leeds. She is Co-Chair of the Trainees and Members & Committee, a Fellow of the Higher Education Academy, and is currently undertaking a PhD. Recording date: 9 June 2025 -- Follow us -- https://www.instagram.com/rcpedintrainees https://twitter.com/RCPEdinTrainees -- Upcoming RCPE events -- https://www.rcpe.ac.uk/events -- Become an RCPE Member -- https://www.rcpe.ac.uk/membership/join-college Feedback: cme@rcpe.ac.uk

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Fudman, MD As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn's disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Fudman, MD As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn's disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.

Ask Flora Funga Podcast anything OR Leave a Review     Stephanie Karzon Abrams, a neuropharmacologist with a Master of Science in Clinical Pharmacology, is the founding advisor of Beyond Consulting, where she offers science, research, and strategy solutions for organizations in the plant medicine and psychedelic sectors. With a background in clinical research and industry experience at Johnson & Johnson, Stephanie blends scientific expertise with strategic insight to pioneer innovative approaches in integrative healthcare. Her passions span women's health, plant medicine, neurology, and music, and she actively advocates for public education and access to alternative therapies. As a prescriber for MDMA and psilocybin therapy through Canada's Special Access Program and a scientific advisor for the Microdosing Collective, Stephanie is deeply involved in advancing psychedelic medicine. She also co-founded initiatives like Public Secret, Mt. Mushmore, and The Last 6, which merge music, community building, and health education to foster connection and healing. All Links mentioned on florafungapodcast.com/167Wear FFP merch to support the show and impress your friends & family Zbiotics: "FLORA10"Drink ZBiotics before drinking alcohol-Alcohol produces acetaldehyde, a byproduct that your next daySupport the show***I am an affiliate with ENERGYBITS (your daily algae tablet packed with nutrients) go visit this link and use code FLORAFUNGA at checkout for 20% off***Get 20% off Sovereignty use code "KK20" Zbiotics: "FLORA10"Drink ZBiotics before drinking alcohol-Alcohol produces acetaldehyde, a byproduct that your next day SUPPORT THE SHOW: Join my Patreon for only $1/month [THATS only .03 cents a day!]Follow my other social media sites to interact and engage with me:Email me to be on the podcast or inperson Interview: floraandfungapodcast@gmail.com FacebookInstagramTwitterTikTokYouTubePatreon Help support my plant buying habit by "Buying me a Plant"a twist on buy me a coffee

Welcome to the podcast with Dr. Brendan McCarthy!   Can you start hormone replacement therapy (HRT) or bioidentical hormones without lab testing? Technically—yes. But should you? In this episode, Dr. Brendan McCarthy, Chief Medical Officer of Protea Medical Center, shares his medical perspective on why skipping labs could put your health at risk. Responding to viral videos that suggest lab work is unnecessary, Dr. McCarthy walks you through: ✅ Why objective data matters—especially for hormone care ✅ The dangers of prescribing hormones without testing ✅ How HRT can be safely and affordably customized ✅ Real-life clinical scenarios that show the power of lab-guided treatment Whether you're navigating perimenopause, menopause, or curious about functional medicine, this episode aims to inform—not attack—and to elevate the standard of care all patients deserve.   Dr. Brendan McCarthy founded Protea Medical Center in 2002. While he's been the chief medical officer, Protea has grown and evolved into a dynamic medical center serving the Valley and Central Arizona. A nationally recognized as an expert in hormone replacement therapy, Dr McCarthy s the only instructor in the nation who teaches BioHRT on live patients. Physicians travel to Arizona to take his course and integrate it into their own practices. Besides hormone replacement therapy, Dr. McCarthy has spoken nationally and locally before physicians on topics such as weight loss, infertility, nutritional therapy and more.   Citations: - O'Connell, Mary Beth. "Pharmacokinetic and pharmacologic variation between different estrogen products." The Journal of Clinical Pharmacology 35.9S (1995): 18S-24S.. - Qureshi, Rehana, et al. "The major pre-and postmenopausal estrogens play opposing roles in obesity-driven mammary inflammation and breast cancer development." Cell metabolism 31.6 (2020): 1154-1172.. - Bagot CN, Marsh MS, Whitehead M, Sherwood R, Roberts L, Patel RK, Arya R. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010 Aug;8(8):1736-44. doi: 10.1111/j.1538-7836.2010.03953.x. Epub 2010 Jun 14. PMID:   Thank you for tuning in and don't forget to hit that SUBSCRIBE button! Let us know in the COMMENTS if you have any questions or what you may want Dr. McCarthy to talk about next!   Check out Dr. Brendan McCarthy's Book! https://www.amazon.com/Jump-Off-Mood-...   -More Links- Instagram: www.instagram.com/drbrendanmccarthy TikTok: www.tiktok.com/drbrendanmccarthy Clinic Website: www.protealife.com

Send us a textWelcome back Rounds Table Listeners! We are back this week with a special podcast episode. Dr. Mike Fralick sits down with Dr. David Juurlink, pharmacologist and internist, Professor of Medicine at the University of Toronto, and head of the Clinical Pharmacology and Toxicology division at Sunnybrook Health Sciences Centre, to chat about the top drug interactions you might be missing. Here we go!Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Spontaneous adverse event reporting from healthcare professionals and patients is a cornerstone in pharmacovigilance systems. Unfortunately, it is a well-known issue that only a fraction of events is reported. To further complicate matters, poor quality reports present a significant challenge for pharmacovigilance assessors. In Uganda, several new routes have been introduced to facilitate reporting for patients and healthcare professionals, including email, WhatsApp and the Med Safety smartphone app. Henry Zakumumpa is a researcher at Makerere University in Kampala, Uganda. He has recently performed a qualitative study to learn more about drivers and obstacles for quality in adverse event reporting from patients and healthcare professionals in Uganda. He joins the Drug Safety Matters studio to help us get a more nuanced picture of challenges and opportunities around the issue.  Tune in to find out:Why are HIV patients in Uganda reluctant to report adverse events to their healthcare providers?What are the challenges with reporting via WhatsApp?How can regulators and PV centres foster better quality in incoming adverse event reports? Want to know more?Listen to Henry talk about the safety of HIV medications in this 2022 episode of Drug Safety Matters.Visit this CARTA (Consortium for Advanced Research Training in Africa) profile page to learn more about Henry's research.Improving the spontaneous reporting of suspected adverse drug reactions: An overview of systematic reviews (British Journal of Clinical Pharmacology, 2023)Improving adverse drug event reporting by healthcare professionals (Cochrane Database Systematic Review, 2024) Join the conversation on social mediaFollow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we work to advance medicines safety.

We continue our Project Optimus series with a focus on clinical pharmacology—a foundational element in redefining dose optimization in oncology drug development. Dr. Wael Harb is joined by Pierre-Olivier Tremblay, Vice President of Clinical Pharmacology at Syneos Health, to discuss how model-informed strategies, exposure-response analysis and biomarkers are transforming early phase trials. They examine how tools like PK/PD modeling and tumor dynamics simulations enable a shift from traditional maximum tolerated dose approaches to more patient-centric dosing strategies, and explore how AI, data sharing and regulatory innovation are shaping the future of precision oncology.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Guest: Martin Cheatle, PhD A thoughtful, communicative, and compassionate approach to opioid use is essential for responsible patient use. Join Dr. Martin Cheatle as he explains the neuroscience of chronic pain, the psychosocial components often overlooked in these patients, and evidence-based strategies for evaluating risk and treatment response. Dr. Cheatle is the Director of Behavioral Medicine at the Penn Pain Medicine Center as well as an Associate Professor of Psychiatry, Anesthesiology, and Critical Care and the Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction at the University of Pennsylvania. He also presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.

Guest: Martin Cheatle, PhD A thoughtful, communicative, and compassionate approach to opioid use is essential for responsible patient use. Join Dr. Martin Cheatle as he explains the neuroscience of chronic pain, the psychosocial components often overlooked in these patients, and evidence-based strategies for evaluating risk and treatment response. Dr. Cheatle is the Director of Behavioral Medicine at the Penn Pain Medicine Center as well as an Associate Professor of Psychiatry, Anesthesiology, and Critical Care and the Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction at the University of Pennsylvania. He also presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.

CME credits: 0.75 Valid until: 08-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-experts-preventing-and-managing-cmv-post-solid-organ-transplant/32966/ Join experts, Fernanda P. Silveira, MD, MS, FIDSA, FAST and Jennifer Saullo, MD, PharmD, FIDSA, as they delve into the complexities of cytomegalovirus (CMV) prevention and treatment following solid organ transplantation (SOT). Presentations will feature detailed case discussions with a focus on managing resistant and refractory disease, addressing treatment-related toxicities, and optimizing therapeutic strategies. This program is an essential primer on the scientific challenges and solutions in this critical area of transplant medicine. =

CME credits: 0.75 Valid until: 08-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-experts-preventing-and-managing-cmv-post-solid-organ-transplant/32966/ Join experts, Fernanda P. Silveira, MD, MS, FIDSA, FAST and Jennifer Saullo, MD, PharmD, FIDSA, as they delve into the complexities of cytomegalovirus (CMV) prevention and treatment following solid organ transplantation (SOT). Presentations will feature detailed case discussions with a focus on managing resistant and refractory disease, addressing treatment-related toxicities, and optimizing therapeutic strategies. This program is an essential primer on the scientific challenges and solutions in this critical area of transplant medicine. =

You can text us here with any comments, questions, or thoughts!In this encore episode, Kemi welcomes Dr. Tamorah Lewis, a neonatologist and pediatric clinical pharmacologist, to discuss the intricate dance of motherhood and career. Together, they explore the challenges and triumphs of being high-achieving women of color in academia.   Join Kemi and Dr. Lewis as they candidly reflect on their personal journeys, the evolving definition of success in motherhood, the vital role of supportive partnerships and the intentional steps we can take to empower our children.  Highlights from this episode: Embracing Imperfections in Motherhood The Importance of Self-Worth and Identity Navigating Career and Family Dynamics The Role of Support Systems in Parenting Redefining Success as a Working Mother  Loved this convo? Please go find Dr. Lewis on X (fka Twitter) @TamorahLewisMD and show her some love!  More about Dr. Tamorah Lewis, MD, PhD - Dr. Tamorah is a physician scientist and the Division Head for Clinical Pharmacology and Toxicology at SickKids. In this role, her goal is to advance the hospital-wide vision for Precision Child Health and collaborate with multiple clinical Divisions to research and implement precision therapeutics. She will provide clinical care in the Level IV NICU at SickKids. Prior to this new role, Lewis was at Children's Mercy Kansas City in the Divisions of Neonatology and Pediatric Clinical Pharmacology for seven years. She worked as an attending in the Level IV NICU and led translational / clinical research in neonatal pharmacology.  If you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations.  REMINDER: Your Unapologetic Career Podcast now releases episode every other week! Can't wait that long? Be sure you are signed up for our newsletter (above) where there are NEW issues every month! 

Guest: Andre Harvin, PharmD, MS, MBA Biosimilars have greatly impacted the US healthcare system over the last decade, creating cost savings and increasing access for patients.1,2 However, although some biosimilars have seen significant adoption, not all biosimilars have been able to achieve sustainable market use.1 Learn about the barriers to biosimilar adoption in the US and strategies for overcoming them from Dr. Andre Harvin. Dr. Harvin is the chief pharmacy officer at Cone Health in Greensboro, North Carolina. References: AAM, The U.S. Generic & Biosimilar Medicines Savings Report, September 2023 IQVIA Institute for Human Data Science, Biosimilars in the United States 2023-2027: Competition, Savings, and Sustainability, January 2023 © Fresenius Kabi USA, LLC 2025 03/2025

Den här gången går vi igenom en något invecklad historia som tidigare aldrig beskrivits i detalj, men som innehåller ett exempel på storskalig amerikansk kopiering av östeuropeisk teknologi under kalla kriget, hallucinerande apor, ett mystiskt motgift och en koppling till Israel via CIA.  Vi försöker nysta upp det hela steg för steg och förklara varför det är principiellt intressant samt ta upp en oväntad vinkel av särskild relevans för de med svår allergi än idag. Källorna inkluderar allt från CIA:s arkiv till gamla farmakologiska tidskrifter, en tidigare hemligstämplad tjeckoslovakisk forskningsartikel, och mycket annat (därför blir källförteckningen nedan ett urval snarare än uttömmande).Länk till den öppna föreläsningen på FHS den 7 maj:https://www.fhs.se/arkiv/kalenderhandelser/2025-02-12-hotbilder-fran-genetisk-teknologi.htmlKällor (ett urval):Washington Post-artikeln (1984):https://www.cia.gov/readingroom/docs/CIA-RDP90-00965R000100130039-8.pdf"Assessment of the Weapons and Tactics Used in the October 1973 Middle East War" (1974), Weapons Systems Evaluation Group:https://www.cia.gov/readingroom/docs/LOC-HAK-480-3-1-4.pdf"Chemical Warfare: Progress and Problems in Defensive Capability" (1986). US General Accounting Office, Washington D.C.Kreicer, M. (1967), Nekatorie sposobi rasceta dozirovok dlja celoveka ishodjascih na rezultatov polucennih na podopitnih zivotnih (Rus.). Sbornik Vedeckych Praci, 25, 27-71"Nervgasmotmedel: aktuellt kunskapsläge" (2005), FOI:https://www.foi.se/rest-api/report/FOI-R--1610--SEVojvodic, V. B. & M. Maksimovic (1972). "Absorption and Excretion of Pralidoxime in Man after Intramuscular Injection of PAM-2CL and Various Cholinolytics", European Journal of Clinical Pharmacology 5, 58-61Von Bredow, Jürgen D. et al. (1991). "Effectiveness of Oral Pyridostigmine Pretreatment and Cholinolytic-Oxime Therapy against Soman Intoxication in Nonhuman Primates", Fundamental and Applied Toxicology 17, 761-770

At the 2025 National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to medicine—will be much discussed. In this curtain raiser, BioSpace speaks with conference chair Prathap Nagaraja Shastri of J&J about these highly anticipated topics. HostJef Akst, Managing Editor, BioSpaceGuestPrathap Nagaraja Shastri, Scientific Director and Group Leader, Clinical Pharmacology and Pharmacometrics, Johnson and JohnsonBioSpace is a media partner of the National Biotechnology Conference.

In this episode of BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe continue their conversation with Dr. Nathan Teuscher, a seasoned expert in clinical pharmacology and pharmacometrics. They discuss the challenges and opportunities presented by new technologies, particularly in drug development and patient engagement. The conversation highlights the evolution of pharmaceuticals, and the potential of virtual clinical trials. In this conversation, Nathan Teuscher discusses the importance of optimizing drug dosages in oncology, the challenges faced in cell therapy, and the complexities of treating immunocompromised patients. He emphasizes the need for collaboration in the scientific community and shares his perspective on measuring success in life and career. Additionally, Nathan talks about his podcast, Clinical Pharmacology (https://creators.spotify.com/pod/show/clinical-pharmacology), which aims to educate listeners on clinical pharmacology and related topics. Chapters 00:51 The Changing Landscape of Pharmaceuticals 03:49 Virtual Clinical Trials and Patient Engagement 08:06 Optimizing Drug Dosage in Oncology 10:55 New News! - FDA Approvals (Mesoblast) and Challenges in Cell Therapy 14:26 The Complexities of Cell Therapy 17:33 Navigating Immunocompromised States in Treatment 20:09 Advice to Young Scientists in Biopharma  23:04 Defining Success in Life and Career 24:47 The Purpose and Impact of Nathan's Podcast, Clinical Pharmacology HOW TO REACH US: Nathan Teuscher https://www.linkedin.com/in/nathanteuscher/  Aplos Analytics - https://aplosanalytics.com/  Email: nathan@aplosanalytics.com Nathan Teuscher's Podcast: Clinical Pharmacology Podcast https://teuschersolutions.com/  Collaboration with BioTalk Unzipped (Ep. 40) https://podcasts.apple.com/us/podcast/collaboration-with-biotalk-unzipped-ep-40/id1695617234?i=1000682122951  Podcast (on Spotify): https://creators.spotify.com/pod/show/clinical-pharmacology Podcast (on Apple): https://podcasts.apple.com/us/podcast/clinical-pharmacology-podcast-with-nathan-teuscher/id1695617234 Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/  Celerion - https://www.celerion.com/   Gregory Austin https://www.linkedin.com/in/gregoryaustin1/  ECI - https://eci-rx.com /  Takeaways Nathan Teuscher has over 20 years of experience in clinical pharmacology and pharmacometrics. Virtual clinical trials can enhance patient engagement and diversity in research. Finding the right dosage is a critical challenge in drug development. Project Optimus aims to redefine oncology drug development practices. AI and data analysis can help identify ideal candidates for clinical trials. Ethical considerations are paramount in the use of patient data for research. The right dose for each patient varies significantly. Understanding individual immune system capacities is crucial in treatment. Collaboration is key to success in the scientific community. Success is measured by the happiness of loved ones. Finding joy in helping others is essential for career fulfillment. Podcasts serve as valuable educational resources. Engaging with diverse disciplines enhances scientific understanding. Sound Bites “If you want to be successful, seek first to understand, then be understood.” “If you're looking to help people and in collaboration, you'll be successful.” “Success in life is the happiness of loved ones around you.” New News Story:  After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy https://www.fiercepharma.com/pharma/fda-nod-gvhd-cell-therapy-gives-australian-biotech-mesoblast keywords BioTalk, pharmacology, AI in pharma, drug development, Nathan Teuscher, pharmacometrics, virtual clinical trials, clinical research, pharmaceuticals, virtual trials, healthcare innovation, drug development, patient engagement, medical technology, drug dosage, oncology, FDA approval, cell therapy, immunocompromised, collaboration, success, clinical pharmacology, podcast, healthcare

This month we are joined by Sarah Branson (Coram Chambers) and Professor James Coulson (Professor in Clinical Pharmacology and Toxicology at Cardiff University).  We discuss the concern that over-reliance on the numbers generated in hair testing can lead to miscarriages of justice.  The issue is that the use of a standardised cut-off levels have a racial bias, because the dark melanin in the hair helps to incorporate the drugs in the hair so someone with black hair will have a much higher reading than someone with red or blond hair, even if they have used the same amount of drugs over the same period of time.  Sarah recommends that from now on when hair testing is commissioned that it has to be instructed like other expert evidence – with a letter of instruction, there is a full forensic history.  Sarah has drafted a template LOI and order which you can access on the Coram website: https://www.coramchambers.co.uk/resources/hair-strand-testing-resources/ James makes the point that in other Courts (like to civil, criminal or coroners courts) it is unusual to have an analytical chemist commenting on the wider interpretation of the result.  James agrees that it is very important that evidence is not seen in isolation.  James takes us through the information that he would to see in these instructions in the future.  Sarah reminds us that we should start thinking about this evidence as expert opinion evidence rather than elevating the presumptive weight that should be given to the evidence.  Sarah directs us to the judgment of Lord Peter Jackson in D, Re (Children: Interim Care Order: Hair Strand Testing) [2024] EWCA Civ 498 (10 May 2024)https://www.bailii.org/ew/cases/EWCA/Civ/2024/498.html.  Sarah points out the numbers from a test is the science but what those numbers mean is just someone's opinion like any other expert evidence.  During the discussion, Sarah and James refer to:  The incorporation of drugs into hair: relationship of hair color and melanin concentration to phencyclidine incorporation M H Slawson, D G Wilkins, D E Rollins J Anal Toxicol 1998 Oct 22. The effect of hair color on the incorporation of codeine into human hair. Rollins DE, Wilkins DG, Krueger GG, Augsburger MP, Mizuno A, O'Neal C, Borges CR, Slawson MH.J Anal Toxicol. 2003 Nov-Dec;27(8):545–51. doi: 10.1093/jat/27.8.545. Cuypers E, Flanagan RJ. The interpretation of hair analysis for drugs and drug metabolites. Clin Toxicol (Phila). 2018 Feb;56(2):90-100.  Forensic Science Internation (2018)

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Stephanie Karzon Abrams, a neuropharmacologist and founding advisor of Beyond Consulting. Find full show notes and links here:  https://thethirdwave.co/podcast/episode-276-stephanie-karzon-abrams With her unique background spanning clinical pharmacology, corporate healthcare, and the music industry, Stephanie shares insights on the intersection of psychedelic science, integrative medicine, and community building. She discusses the transformative potential of psychedelics from a neuropharmacological perspective, her work supporting ketamine clinics and plant medicine brands, as well as her journey from traditional healthcare to pioneering innovative approaches in the psychedelic space. Stephanie Karzon Abrams, a neuropharmacologist with a Masters of Science in Clinical Pharmacology, is the founding advisor of Beyond Consulting, providing science, research, operations, and strategy solutions to organizations in the natural product, plant medicine, and psychedelic sectors. Her career spans from clinical research and Johnson & Johnson to pioneering innovative healthcare approaches. Beyond her scientific work, she co-creates community initiatives including Public Secret music label and Mt. Mushmore educational dinner series. As a prescriber for MDMA and psilocybin therapy through Canada's Special Access Program and scientific advisor for the Microdosing Collective, she champions the integration of cutting-edge therapeutic approaches with traditional healthcare. Her work focuses on bridging scientific expertise with strategic thinking to advance innovative healthcare solutions. Highlights: Origins of Public Secret record label and global groove music collective Rich cultural background and journey from Montreal to California Stephanie breaks down clinical psychopharmacology Mount Mushmore Transition from J&J to psychedelic medicine consulting Stephanie's firm, Beyond Consulting Supporting ketamine clinics and integrative medicine centers Deep dive into neuropharmacology of psychedelics vs traditional medications Microdosing applications for ADHD and anxiety Importance of lifestyle changes alongside psychedelic protocols Managing work-life balance in the psychedelic industry Links: Beyond Consulting Public Secret Music Label Microdosing Collective Episode Sponsors: The Practitioner Certification Program by Third Wave's Psychedelic Coaching Institute.

Bridging science and spirit, Stephanie Karzon Abrams chats with Raghu about integrating psychedelics and soul into the medical community.This time on Mindrolling, Raghu and Stephanie delve into: Out-of-body experiences through musicAddressing identity changes after Traumatic Brain InjuriesUtilizing plants to promote better healthReconnecting to ourselves through psychedelic therapiesTrauma from displacement and immigrationBridging science and spirit by integrating holistic views into medicineThe mental health impact of physical health issuesGetting the medical world to want to heal the mind and soul as well as the physicalThe ways that psychedelic experiences can change usThe importance of having a guide through psychedelic experiencesSitting with discomfort and being open to the lessonsHow music expands our minds and creates a space for connectionAbout Stephanie Karzon Abrams:Stephanie Karzon Abrams, a neuropharmacologist with a Masters of Science in Clinical Pharmacology, is the founding advisor of Beyond The Bench consultancy. The firm provides science, research, operations, and strategy solutions to organizations and clinics in the natural product, plant medicine, and psychedelic sectors. A recognized leader in shaping the future of integrative and innovative healthcare, Stephanie Karzon Abrams champions the exploration of novel therapeutic approaches. Her interests extend beyond neurology, encompassing plant medicines, women's health, and the potential of music to enhance healing. Check out Stephanie's music label, Public Secret.“Anybody who has any kind of health challenge will have their mental health affected. There is an impact. Just treating that illness or symptom is not enough; you need to heal the mind. You need to heal the soul. They're all interconnected. There's no reason why medical science, especially when we talk about psychedelics, can't address all of that. For me, that's the ultimate goal, if I can use research as a tool to achieve this then I've succeeded.” – Stephanie Karzon AbramsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr Camidge sits down with Jeanne Fourie Zirkelbach, PhD, a clinical pharmacologist in the Office of Clinical Pharmacology in the Center for Drug Evaluation and Research at the FDA.  Drs Camidge and Zirkelbach discuss how Zirkelbach got her start in the pharmacokinetics field; her involvement with Project Optimus, an initiative by the FDA's Oncology Center of Excellence that works to reform dose-optimization and -selection paradigms in oncology drug development; and how her research with patient-reported outcomes emphasizes the importance of keeping patient needs, preferences, and experiences at the forefront of drug development to minimize the effects of cancer treatment on quality of life.

Guidance Recap Podcast | Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies

What if we could redefine what it means to be healthy by setting new medical standards? What if medicine could go beyond treating symptoms and treat root causes?In this episode, the brilliant Dr. Shai Efrati enlightens us on a revolutionary concept, enhanced medicine, which goes beyond conventional treatments and focuses on the body's natural healing abilities. Dr. Shai Efrati is a renowned Physician and Professor at Tel Aviv University, specializing in Internal Medicine, Nephrology, Clinical Pharmacology, and Hypertension. He is also a pioneer in hyperbaric medicine and the Author of "Beyond Normal: How the New Science of Enhanced Medicine Elevates Peak Performance and Repairs Brain Injuries."Throughout this episode, you'll learn what enhanced medicine is, why it is so revolutionary, and how it can change how we see medical attention, treatments, and self-care. You'll also hear Dr. Efrati's thoughts on the importance of focusing on root causes, personalized approaches to improve patient care, the multiple benefits of hyperbaric chambers, and much more.Tune in to episode 445 of Becoming Your Best and discover why enhanced medicine can change how we think about health and wellness.Some Questions I Ask:Tell us about your book "Beyond Normal" and why you wrote it (2:10)Let's take someone who has been having headaches for a year and hasn't figured out why. Using your approach, what would you do with that individual? (9:50)In This Episode, You Will Learn:Dr. Efrati explains the hyperoxic-hypoxic paradox and hyperbaric chambers (6:40)Why understanding the core biology of symptoms and interdisciplinary approaches is crucial (15:00)Dr. Eftati's golden definition of what it means aging (27:40)Connect with Dr. Shai Efrati:WebsiteLinkedInYouTubeBook: Dr. Shai Efrati - Beyond Normal: How the New Science of Enhanced Medicine Elevates Peak Performance and Repairs Brain InjuriesBecoming Your Best Resources:Becoming Your Best WebsiteBecoming Your Best University WebsiteBecoming Your Best LibraryEmail: support@becomingyourbest.comBook: Becoming Your Best: The 12 Principles of Highly Successful LeadersBook: Conquer Anxiety: How to Overcome Anxiety and Optimize Your PerformanceFacebook Group – Conquer Anxiety Hosted on Acast. See acast.com/privacy for more information.

Our guest's journey with cannabis began as a youthful experiment but transformed into a profound exploration of its medicinal and truth-telling properties. In this episode of Consciously Cannabis, Stephanie Karzon shares her evolution with cannabis, moving from casual use to a deeper appreciation for its potential for mental and physical wellness. From setting up an integrative medicine clinic in LA to understanding the holistic approach to women's health, Stephanie shares insights into combining Western medical practices with alternative therapies. We explore the significance of treating the whole person rather than just symptoms and the potential of psychedelic therapies in neurological and women's health. We also journey through the multifaceted world of psychedelic-assisted therapy, emphasizing the necessity of safe, structured environments. From the rich historical context of psychedelics to their benefits in clinical settings, we explore how these substances can foster acceptance and support, especially among women facing societal pressures. Wrapping up with reflections on gratitude and self-exploration, we discuss how integrating plant-based therapies into daily routines can enhance emotional well-being and personal growth. Join us for an enlightening conversation on harnessing the power of cannabis and psychedelics for holistic health! Guest bio: Stephanie Karzon Abrams, a neuropharmacologist with a Master of Science in Clinical Pharmacology, is the founding advisor of Beyond The Bench consultancy. The firm provides science, research, operations, and strategy solutions to organizations and clinics in the natural product, plant medicine, and psychedelic sectors. A recognized leader in shaping the future of integrative and innovative healthcare, Stephanie Karzon Abrams champions the exploration of novel therapeutic approaches. Her interests extend beyond neurology, encompassing plant medicines, women's health, and the potential of music to enhance healing. Stephanie is a dedicated advocate for public education and strives to redefine the landscape of health and wellness through open-access education and public speaking. Her passions extend to community building, philanthropy, and music, with a particular focus on integrating her passions through unique gatherings and initiatives that foster connection. Stephanie is the co-creator of Public Secret, a music label, management agency, and artist collective; Mt. Mushmore, Higher Elevation, a social and educational dinner series; and The Last 6, a community organization that educates and funds research for the acute childhood illness, Kawasaki disease. Stephanie's career path transcends traditional boundaries, blending her deep scientific expertise with strategic thinking and a passion for exploring innovative healthcare solutions. Her foundation lies in rigorous research, followed by experience at Johnson and Johnson (Biosense Webster) where she honed her operational, strategic planning, and key opinion leader (KOL) engagement skills. Stephanie's current work as a prescriber of MDMA and psilocybin therapy for the Canadian Special Access Program (SAP), and her role as a scientific advisor for the Microdosing Collective, exemplifies her commitment to advancing these emerging fields. Thanks for listening to another episode. Follow, review, and share to help Consciously Clueless grow! Connect with me: https://www.consciouslycarly.com/ Join the Consciously Clueless community on Patreon: https://www.patreon.com/consciouslycarly Connect on Instagram: https://www.instagram.com/consciously.carly/ Connect on Facebook: https://www.facebook.com/consciously.carly.blog Music by Matthew Baxley

Dr. Oren Cohen, President of Clinical Pharmacology and Chief Medical Officer at Fortrea, a global CRO spun-off from Labcorp, discusses the contract research environment and how it continues to change to meet the need for increased productivity in the development and testing of new drugs, devices, and treatments. One key goal is to work in close partnership with clients to include the patient's voice in trial design to increase diversity, drive recruitment, and improve retention.   Oren explains, "I think with all the pressure the industry is under productivity pressure, that's changed massively. It's a very heavy responsibility because we are entrusted with developing very precious intellectual property that represents the next generation of therapeutics for patients affected by all the diseases out there, from rare diseases to cancer to neurodegenerative diseases like Alzheimer's. It's a very exciting time. I think the science is moving very quickly, and we have the good fortune to be working on some very promising and super interesting potential products." "There's lots of innovation in every aspect of clinical trials, from design through process and execution to analysis. So yes, all that is on the table. I would say that our preferred method of engagement is to partner with our clients to get to the best place in terms of what advances science. What is necessary from a regulatory perspective to push a product along toward approval, to show its mettle? What is best for patients and sites responsible for recruiting them?" "It's a natural marriage because our sponsors, the biopharmaceutical companies we serve, obviously have the best expertise for the particular molecule they're studying. They've potentially discovered it, they have it in their portfolio, and they obviously know a lot about it." #Fortrea #ClinicalTrials #DrugDevelopment #PatientVoice #ClinicalTrialDesign #CRO #ContractResearchOrganization fortrea.com Download the transcript here

Dr. Oren Cohen, President of Clinical Pharmacology and Chief Medical Officer at Fortrea, a global CRO spun-off from Labcorp, discusses the contract research environment and how it continues to change to meet the need for increased productivity in the development and testing of new drugs, devices, and treatments. One key goal is to work in close partnership with clients to include the patient's voice in trial design to increase diversity, drive recruitment, and improve retention.   Oren explains, "I think with all the pressure the industry is under productivity pressure, that's changed massively. It's a very heavy responsibility because we are entrusted with developing very precious intellectual property that represents the next generation of therapeutics for patients affected by all the diseases out there, from rare diseases to cancer to neurodegenerative diseases like Alzheimer's. It's a very exciting time. I think the science is moving very quickly, and we have the good fortune to be working on some very promising and super interesting potential products." "There's lots of innovation in every aspect of clinical trials, from design through process and execution to analysis. So yes, all that is on the table. I would say that our preferred method of engagement is to partner with our clients to get to the best place in terms of what advances science. What is necessary from a regulatory perspective to push a product along toward approval, to show its mettle? What is best for patients and sites responsible for recruiting them?" "It's a natural marriage because our sponsors, the biopharmaceutical companies we serve, obviously have the best expertise for the particular molecule they're studying. They've potentially discovered it, they have it in their portfolio, and they obviously know a lot about it." #Fortrea #ClinicalTrials #DrugDevelopment #PatientVoice #ClinicalTrialDesign #CRO #ContractResearchOrganization fortrea.com Listen to the podcast here

In this week's episode, Danie du Plessis, Executive Vice President, Pharmaceutical Operations, Kyowa Kirin, sits down with the EMJ GOLD team to share the value that patient partnerships can hold in the industry. Danie explores how patient partnerships have evolved over the years, what companies should be doing to get them to their best potential, the value of learning from others and much more. A little more on EMJ GOLD's guest… After completing his medical studies and a Master's Degree in Clinical Pharmacology in South Africa, Danie spent three years working in a primary care setting including his own private practice. He joined the pharmaceutical industry in 1993, worked in medical affairs, marketing and sales, pharmacovigilance and clinical operations. He has held roles such as including Senior Vice President and Head of Worldwide Medical Affairs at GlaxoSmithKline. Danie joined Kyowa Kirin International in August 2019 as head of Medical Affairs and has been Executive Vice President Pharmaceutical Operations since April 2024.  He is also a Director and Chair of the Global non-profit Medical Affairs Professional Society (MAPS) Board, Fellow of the Faculty of Pharmaceutical Medicine in the UK, visiting senior lecturer at King's College, London and an affiliate member of the Association for Professional Executive Coaching and Supervision (APECS). 

On this episode, Susan McCune, MD (VP, Pediatrics & Clinical Pharmacology, The PPD Clinical Research Business of Thermo Fisher Scientific) and Jacqui Whiteway, PhD (Senior Director & Pediatric Strategy Liaison, Center for Pediatric Clinical Development, ICON plc) join the podcast to discuss what makes pediatric clinical trials unique and how industry can make participation easier for pediatric patients and their families.They dive deeper into the role that compassion plays in designing successful trials, the importance of including pediatric patients and families in trial protocol design, and creative tools to boost patient engagement

Guidance Recap Podcast | Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics

Youtube https://youtu.be/2wiIZNf8aT0 https://integral-clinic.com Dr. Torres is a Medical Doctor(MX), a licensed acupuncturist, and has a Master's Degree in Chinese Medicine (TCM). While she has not been in practice for quite 3,000 years, she is one of Chicago's most experienced and respected holistic practitioners. “Let's treat your mind, body, and spirit to achieve a whole new level of well-being. Dr. Cristina Torres has always been interested in solving health problems for people. She received her medical degree from the UNAM Autonomous University of Mexico in Mexico City. Dr. Torres extended her studies at UNAM to earn an additional Diploma in Clinical Pharmacology. Several years of practicing medicine in Mexico were followed by working in the private industry where she was involved in pharmaceutical product development, regulation, and compliance. While conducting clinical trials she participated in initiatives to promote good clinical practices, patient rights, and their protection while participating in clinical trials in Mexico and Latin America. Ms. Torres desired, however, to return to direct contact with patients in a holistic way. While living in the United States she discovered that Traditional Chinese Medicine would offer what she was looking for in terms of practicing medicine and patient treatment. She pursued a Master's degree in Traditional Chinese Medicine at the Pacific College of Oriental Medicine in Chicago and obtained Certification from NCCAOM. She also has board certification as a Hypnotherapist from the American Board of Hypnotherapy. Dr. Torres is considered a holistic practitioner as she applies one or more modalities to support patients healing, she has a private practice in Illinois where she is part of a network of practitioners aimed at the prevention and early management of diseases.

Listen to Dr Charly Annesley (Consultant Learning Disability physician) and Dr Rebecca Kuruvilla (RCP clinical education fellow and Clinical Pharmacology and GIM registrar) discuss health inequalities in the population of patients living with a learning disability and why we need more physicians who are trained in this area of medicine. They also talk to Dr Alex Tyler who is an ST6 registrar in Geriatrics and GIM who is completing a PG certificate in Medical Practice in Adult Learning Disability.Dr Charly Annesley is a consultant learning disability physician. She works at North Middlesex University hospital in London, having set up the first and only post of its kind in the country. She is also an honorary clinical lecturer and course lead for a postgraduate certificate in Learning Disability Medicine that is run with the RCP and Edge hill university.Links: Training Programme to meet the Medical Needs of Adults with a Learning Disability | RCP LondonLearning from Lives and Deaths - people with a learning disability and autistic people (LeDeR) - King's College London (kcl.ac.uk)BTS clinical statement on aspiration pneumonia | Thorax (bmj.com)BTS Clinical Statement on the prevention and management of community-acquired pneumonia in people with learning disability | Thorax (bmj.com)Master LeDeR 2023 (2022 report) (kcl.ac.uk)RCP Toolkit:  Acute medical care for people with a learning disabilityThis podcast has been made with an educational grant from Bristol-Myers Squibb Pharmaceuticals Limited (“BMS”). BMS has had no input or involvement in the design, development or content of the podcast whatsoever. Sound by bensound.com

Join us as we welcome Dr. Emma Magavern to The Genetics Podcast! In addition to being a medical doctor with an English Literature degree, Dr. Magovern is a Clinical Research Fellow at the Centre of Clinical Pharmacology and Precision Medicine at Queen Mary, Barts, and the London School of Medicine and Dentistry. Emma also works closely with East London Genes and Health, a program dedicated to increasing engagement in a community that is underrepresented in research. Most recently, she published a paper looking at pharmacogenomics in a British South Asian population. Tune in to this interesting episode!

Guidance Recap Podcast | Clinical Pharmacology Considerations for Antibody-Drug Conjugates

Pediatricians, families, and pharmacists are faced with increasing drug costs and a vast array of complex biologic therapies. Up-to-date knowledge on prescribing practice is constantly a need, specifically regarding generics and the availability of biosimilar and interchangeable biosimilar agents. According to a report from the Association for Accessible Medicines, the U.S. healthcare system saved $408 billion from using generic and biosimilar drugs in 2022, a huge jump from the $195 billion in savings accumulated in 2013. In today's episode, we have a rare opportunity to learn critical knowledge about this topic from renowned experts in the field.  We are joined by John Routt Reigart, MD, and Dr. Siu. Dr. Reigart is professor emeritus at the Medical University of South Carolina as well as the chairperson for the American Academy of Pediatrics' (AAP) Committee on Drugs. “I have been recognized in my state, and to some extent nationally, as being an advocate for improved health for children. I feel that it's very important that pediatricians be advocates for effective regulations for their patients,” Dr. Reigart says.  Dr. Siu is a clinical professor, the vice chair for teaching and learning, and the director of faculty mentoring at the Ernest Mario School of Pharmacy at Rutgers University. She is a pediatric pharmacy clinical coordinator and practices at the K. Hovnanian Children's Hospital and Jersey Shore University Medical Center. She has also been appointed to the board of directors of the Board of Pharmacy Specialties and the pediatric pharmacy association liaison for the AAP Section on Clinical Pharmacology and Therapeutics executive committee. “We want to make sure that medications are easily accessible to families and we also want to make sure that they are also cost effective,” Anita Sui, PharmD, says.  This episode was recorded at the 2023 American Academy of Pediatrics National Conference and Exhibition. Some highlights from this episode include:  The difference between biologics and generics  What the orange and purple books are and their roles in the industry  What an interchangeable product is  Patents and exclusivity  What savings could look like with an uptick of biologics and generics    For more information on Children's Colorado, visit: childrenscolorado.org    

Today's episode is about cell therapies, including CAR T-cell theraphy for cancer. I give an overview of cell therapy and the challenges of clinical pharmacology in this new area of research. Links discussed in the show: CAR T-cell Therapy Image You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved

Welcome to our 100th episode! This week we talked to the renowned Dr. David T. Rubin! Dr. Rubin is the Joseph B. Kirsner Professor of Medicine and a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics, an associate investigator at the University of Chicago Comprehensive Cancer Center and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn's & Colitis Foundation, where he also serves as a Board of Trustees member. He is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease.  In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America's Top Physicians (gastroenterology). Additionally, he twice received the ACG's Governor's Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn's & Colitis Foundation's Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He is an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn's and Colitis.Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD which is now in its 3rd edition and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. Episodes from some of Dr. Rubin's UChicago's team: Dr. Alysse Bedell- Gastro PsychologistMichele Rubin, APN- JPouch surgical nurse extraordinaireMarita Kametas- Ostomy Specialist! Dr. David Choi- IBD PharmacistPlease keep in mind that the views and opinions expressed in this program are those of the speakers and should not be considered medical or legal advice. Please consult with your healthcare team on any changes to your disease, diet, or treatment.Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

In 2011, a paper was published in Pharmacogenomics and Personalized Medicine examining the relationship of antidepressants and akathisia side effects in those with genetic mutations in the metabolizing genes of the CYP450 family. In the study, eight of the subjects had committed homicide and many more became extremely violent while on antidepressants. On today's podcast we welcome one of the co-authors, Christopher Crotty, and subject, David Carmichael, to share their stories.Note: This podcast episode is designed solely for informational and educational purposes, without endorsing or promoting any specific medical treatments. We strongly advise consulting with a qualified healthcare professional before making any medical decisions or taking any actions.*If you are in crisis or believe you have an emergency, please contact your doctor or dial 911. If you are contemplating suicide, call 1-800-273-TALK to speak with a trained and skilled counselor.RADICALLY GENUINE PODCASTDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / X (Twitter)Substack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically Genuine—-----------FREE DOWNLOAD! DISTRESS TOLERANCE SKILLS—----------ADDITIONAL RESOURCESLucire, & Crotty, C. (2011). Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmacogenomics and Personalized Medicine, 65. https://doi.org/10.2147/pgpm.s17445 16:00 Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. (2017). Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clinical Pharmacology & Therapeutics, 102(4), 688–700. https://doi.org/10.1002/cpt.69030:00 - Know Your Drugs39:30 - David Carmichael v. GlaxoSmithKline Inc.40:00 - Carmichael, D. Calm, organized, homicidal behaviour – my connection to school shooters. Mad In America.46:15 - RxISK Prescription Drug Side Effects

Kerri Weingard is a founding partner and global chief operating officer at Verified Clinical Trials (VCT). VCT is the largest global research subject database to reduce dual enrollment and prevent protocol violations. Ms. Weingard is also the CEO and founder of Study Scavenger and Clinical Hero. Both companies are dedicated to clinical trial recruitment and education. Ms. Weingard, who is a nurse practitioner, holds a master's degree in science from Stony Brook University. She, before creating VCT and Study Scavenger, has conducted over 500 clinical trials as a research administrator and sub-investigator. She has more than two decades of experience in the field and is a member of a number of professional organizations, including the American Society for Clinical Pharmacology and Therapeutics, the Drug Information Association and the Association of Clinical Research Professionals.  

In this episode In this illuminating episode, we dive deep into the world of proton pump inhibitors (PPIs), commonly prescribed medications for heartburn and acid reflux. While these drugs have brought relief to millions worldwide, recent studies have begun to uncover potential links between PPI use and an increased risk of dementia. We explore the mechanisms that might underlie this association, the clinical implications for patients, and the broader question of how seemingly unrelated conditions might be connected at a molecular level. Whether you're a healthcare professional, a patient on PPIs, or simply someone curious about the intricate web of human health, this episode promises to offer fresh insights into a hotly debated area of medicine. References: Main papers disucssed in this episode: - Northuis, Carin, et al. "Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study." Neurology (2023). https://n.neurology.org/content/early/2023/08/09/WNL.0000000000207747?utm_source=twitter&utm_medium=organic - Gomm, Willy, et al. "Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis." JAMA neurology 73.4 (2016): 410-416. https://jamanetwork.com/journals/jamaneurology/article-abstract/2487379 - Li, Min, et al. "Proton pump inhibitor use and risk of dementia: systematic review and meta-analysis." Medicine 98.7 (2019). - Ortiz-Guerrero, Gloria, et al. "Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences." Neural plasticity 2018 (2018). - Wijarnpreecha, Karn, et al. "Proton pump inhibitors and risk of dementia." Annals of translational medicine 4.12 (2016). - Haenisch, Britta, et al. "Risk of dementia in elderly patients with the use of proton pump inhibitors." European archives of psychiatry and clinical neuroscience 265 (2015): 419-428. - Batchelor, Riley, et al. "Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review." Journal of gastroenterology and hepatology 32.8 (2017): 1426-1435. - Gray, Shelly L., et al. "Proton pump inhibitor use and dementia risk: Prospective population‐based study." Journal of the American Geriatrics Society 66.2 (2018): 247-253. - Ahn, Nayeon, et al. "Do proton pump inhibitors increase the risk of dementia? A systematic review, meta‐analysis and bias analysis." British Journal of Clinical Pharmacology 89.2 (2023): 602-616. Follow us: Join the NEURO Academy: NEUROacademy.com Follow us on social media: Instagram: The Brain Docs @thebraindocs Facebook: The Brain Docs TikTok: @thebraindocs Website: TheBrainDocs.com  

This episode is all about the intersection of motherhood and ambition, particularly for high-achieving Black women!We are so excited to welcome Dr. Tamorah Lewis to the podcast! Dr. Lewis is a physician-scientist (MD PhD), Division Head for Clinical Pharmacology and Toxicology at SickKids in Toronto, Canada and is a proud mother of three children, Quinton (13), Lydia (10), and Elijah (6).  Listen in as Kemi and Tamorah discuss the intricacies of balancing ambition and motherhood. They emphasize the importance of nurturing emotional intelligence, self-worth, and character in their children while recognizing the value of building a supportive village to help them thrive. Highlights from this episode:Redefining success as a working motherChallenges and triumphs of motherhoodThe power of representing Black cultureThe evolving parent-child relationshipRejecting the "Either/Or" narrative and embracing multidimensional roles as working mothersIf you enjoyed this conversation with Tamorah as much as we do, head over to Twitter @TamorahLewisMD and show her some love!And if you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations.

Dr. Dave Kisor, a professor and director of pharmacogenomics at Manchester University. He graduated from The Ohio State University College of Pharmacy in 1986 and completed a two-year fellowship in therapeutic drug monitoring/pharmacokinetics at OSU. Before he joined Manchester, Dave was professor of pharmaceutical sciences at Ohio Northern University after being a research scientist at Burroughs Wellcome Co/GlaxoWellcome. Dave has over 80 peer-reviewed publications including being the lead author on two pharmacogenomics textbooks. He is a past chair of the American Association of Colleges of Pharmacy (AACP) Pharmacogenomics Special Interest Group. Dave was named a Fellow of the American College of Clinical Pharmacology in 2017, and in 2021, along with Dr. Tom Smith, he received an AACP Innovations in PGx Teaching Award. His current research is related to PGx and opioid use disorder. Dave currently serves as co-chair of the Pharmacogenomics Global Research Network (PGRN) Education Committee and is Editor-In-Chief of Pharmacogenomics: Foundations, Competencies, and the Pharmacists' Patient Care Process.